Forward to: Medical Affairs

Research Publication Monitor
Workflows

Ten agent workflows for Medical Affairs — KOL publication tracking, journal impact analysis, preprint monitoring, systematic review intelligence, real-world evidence trends, competitor medical strategy signals, guidelines updates, medical education tracking, publication planning intelligence, and medical affairs dashboard — enabling data-driven medical strategy powered by domain intelligence.

1KOL Publication Tracking

AI agent monitors academic medical center and researcher domains to track key opinion leader publications, citation patterns, and research focus areas across therapeutic categories.

1
Track KOL Research Output
/blog/leadership/pressOpenPageRank
KOL PUBLICATION TRACKER — 500 RESEARCHERS MONITORED ════════════════════════════════════════════════════════ dana-farber.org — Dr. A. Thompson /blog: 14 publications (last 6 months) — focus: ADC combinations PageRank: 8.1 | H-index: 82 SIGNAL: Top ADC KOL — increasing competitor engagement mskcc.org — Dr. L. Patel /leadership: New department chair — cell therapy /blog: NEJM publication on CAR-T resistance mechanisms SIGNAL: Emerging KOL in cell therapy — engage early PUBLICATION VOLUME TRENDS: Our therapeutic areas: 2,400 publications/quarter Competitor-sponsored publications: 62% of high-impact papers SIGNAL: Increase investigator-initiated study support

2High-Impact Journal Monitor

AI agent monitors top medical journal domains for publications relevant to the company pipeline and competitive landscape — tracking NEJM, Lancet, JAMA, and Nature Medicine.

1
Track Journal Publications
/blog/press/aboutOpenPageRank
HIGH-IMPACT JOURNAL TRACKER ════════════════════════════════════════════════════════ nejm.org — This Week New: Phase 3 results — competitor ADC in breast cancer New: Real-world data — GLP-1 cardiovascular outcomes SIGNAL: Competitor data strengthening — prepare response thelancet.com New: Systematic review — gene therapy durability data SIGNAL: Favorable for our gene therapy program nature.com — Nature Medicine New: CRISPR base editing safety profile long-term follow-up SIGNAL: Safety data supportive — cite in regulatory submission

3Preprint & Early Data Intelligence

AI agent monitors preprint servers and early publication domains to detect emerging research findings before peer-reviewed publication — providing an early-warning system for competitive threats.

1
Monitor Preprint Activity
/blog/pressDomain AgesOpenPageRank
PREPRINT INTELLIGENCE ════════════════════════════════════════════════════════ medrxiv.org — Clinical Preprints New: 8 preprints relevant to our pipeline (this week) Notable: Phase 2 competitor data in our key indication SIGNAL: Competitor data 4-6 months ahead of publication biorxiv.org — Basic Science New: Novel drug target validation — our mechanism of interest SIGNAL: Independent target validation supports our program PREPRINT ANALYSIS: Relevant preprints tracked (monthly): 120-150 Conversion to peer-reviewed: 68% within 12 months

4Real-World Evidence Tracking

AI agent monitors RWE study publications and database company domains to track real-world data generation across competitor products and therapeutic areas.

1
Track RWE Generation
/products/blog/case-studiesIAB Categories
REAL-WORLD EVIDENCE INTELLIGENCE ════════════════════════════════════════════════════════ flatiron.com — Oncology RWD /products: 280+ institution network — 3.5M patient records /blog: New RWE publications on IO-chemo combinations SIGNAL: RWE data increasingly influencing label decisions optum.com — Claims + EHR Data /products: 100M+ patient lives covered /case-studies: 14 RWE studies supporting competitor labels SIGNAL: Competitor investing heavily in RWE — match investment RWE PUBLICATION TRENDS: RWE publications (our TAs): 480 this quarter (+18% YoY) Regulatory decisions citing RWE: 12 approvals this year

5Treatment Guidelines Monitor

AI agent monitors medical society and guidelines organization domains to track treatment guideline updates, practice recommendations, and algorithm changes.

1
Track Guideline Updates
/docs/press/eventsOpenPageRank
TREATMENT GUIDELINES TRACKER ════════════════════════════════════════════════════════ nccn.org — NCCN Guidelines Update /docs: NSCLC guidelines v.3.2026 — updated March 2026 Change: Our drug added to preferred 1L regimen SIGNAL: Guideline inclusion drives adoption — prepare MSL asco.org — ASCO Practice Guidelines /docs: New rapid guideline — AI in clinical trial design SIGNAL: AI methodology acceptance advancing GUIDELINES IMPACT: Guideline-aligned prescribing: 85% of oncologists follow NCCN Time from data to guideline: 6-12 months average

6Competitor Medical Strategy

AI agent monitors competitor medical affairs activity by tracking investigator-initiated study programs, medical education investments, and advisory board signals.

1
Analyze Competitor Medical Strategy
/events/press/partnersOpenPageRank
COMPETITOR MEDICAL STRATEGY INTELLIGENCE ════════════════════════════════════════════════════════ merck.com — Medical Affairs Investment /events: 48 sponsored medical education events (Q1) /partners: 22 IIS programs active SIGNAL: Outspending us 3:1 in medical education astrazeneca.com — RWE Strategy /press: $200M RWE investment announced /events: 12 RWE symposia at major conferences SIGNAL: AZ building evidence advantage — respond RECOMMENDATION: Increase IIS funding by 40% in priority TAs Launch RWE generation program — partner with Flatiron

7Systematic Review Intelligence

AI agent monitors systematic review and meta-analysis publications to track evidence synthesis outcomes that inform treatment decisions, guidelines, and health technology assessments.

1
Track Systematic Reviews
/blog/docs/pressOpenPageRank
SYSTEMATIC REVIEW INTELLIGENCE ════════════════════════════════════════════════════════ cochranelibrary.com New: Network meta-analysis — ADCs in breast cancer Result: Our ADC ranked #2 for OS — ahead of 4 competitors SIGNAL: Favorable NMA result — use in HTA submissions nice.org.uk — NICE HTA New: Technology appraisal — competitor gene therapy Result: Cost-effective only with outcomes-based contract SIGNAL: HTA bodies requiring outcomes contracts for gene therapy META-ANALYSIS PIPELINE: Ongoing reviews in our TAs: 14 registered protocols Publication expected: Q2-Q3 2026

8Medical Education Tracking

AI agent monitors continuing medical education provider domains to track educational programs, speaker engagements, and medical education content supporting competitor products.

1
Track Medical Education Landscape
/events/about/partnersIAB Categories
MEDICAL EDUCATION INTELLIGENCE ════════════════════════════════════════════════════════ medscape.com /events: 340 CME programs in our therapeutic areas Competitor-supported: 58% funded by top 3 competitors SIGNAL: Competitor dominating medical education space uptodate.com /about: Treatment algorithm updated — our TA Change: Our drug repositioned as preferred option SIGNAL: Point-of-care content favorable — high impact CME LANDSCAPE: Total CME programs (our TAs): 1,200+ annually Our sponsored programs: 8% of total — below fair share

9Publication Planning Intelligence

AI agent monitors competitor publication patterns to decode publication planning strategies — identifying data suppression, selective reporting, and publication timing around regulatory milestones.

1
Decode Publication Strategy
/investors/press/blogOpenPageRank
PUBLICATION STRATEGY ANALYSIS ════════════════════════════════════════════════════════ competitor-a.com Publication cadence: 8-12 publications/quarter (steady) Timing: Publications cluster around ASCO/ESMO SIGNAL: Well-executed publication plan — predictable competitor-b.com Publication cadence: Dropped from 10 to 3 this quarter /investors: Phase 3 readout delayed SIGNAL: Publication slowdown may indicate negative data OUR PUBLICATION METRICS: Publications (trailing 12 months): 48 High-impact (IF > 20): 6 — need improvement Time from data to publication: 8 months avg — too slow

10Medical Affairs Dashboard

AI agent synthesizes all publication and medical affairs intelligence into an executive dashboard — providing leadership with visibility into evidence landscape, KOL engagement, and competitive medical strategy.

1
Generate Medical Affairs Dashboard
/blog/events/pressOpenPageRankIAB Categories
MEDICAL AFFAIRS DASHBOARD — FEBRUARY 2026 ════════════════════════════════════════════════════════ EVIDENCE LANDSCAPE: Publications tracked: 2,400/quarter in our TAs Guideline updates: 3 favorable this quarter RWE studies: Competitor outpacing us 3:1 KOL ENGAGEMENT: KOLs tracked: 500 | Engaged: 180 (36%) Competitor-aligned: 65% of top 50 CONFERENCE PRESENCE: Next major: ASCO June 2026 Our abstracts submitted: 18 — below peer avg
2
Generate Medical Affairs Report

Medical Affairs Report — February 2026

EXECUTIVE SUMMARY ──────────────────────────────────────── KOLs monitored: 500 across 12 therapeutic areas Publications tracked: 2,400 per quarter Conferences analyzed: 8 major medical meetings RWE databases assessed: 12 platforms KEY INSIGHTS Evidence landscape increasingly competitive — RWE investment critical. KOL engagement gaps in 3 priority therapeutic areas require action. Publication strategy needs acceleration — 8-month lag too slow. Guideline updates favorable — capitalize with MSL engagement. Medical education spend below fair share — increase CME investment.
Get in Touch

Interested in AI Agent Domain Intelligence?

For pricing, subscription options, custom database builds, or enterprise partnerships — contact us below.

Power Your AI Agents with Domain Intelligence

Subscribe to the AI Agent Domain Database — continuous access to 100M+ domains, 20 page types each, quarterly refreshes, and real-time change signals.

AI Agent Database View Pricing

Annual subscription includes quarterly data refreshes, change detection alerts, and priority API access.